Page last updated: 2024-12-07

fk 224

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FK 224: tachykinin receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115228
MeSH IDM0203591

Synonyms (5)

Synonym
fk-224
fk 224
125787-94-2
fr 115224
n-[6-(2-amino-2-oxoethyl)-12-benzyl-9-(1-hydroxyethyl)-3-(hydroxymethyl)-18-[(4-hydroxyphenyl)methylidene]-19,22-dimethyl-15-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1-oxa-4,7,10,13,16,19-hexazacyclodocos-21-yl]-3-(2-pentylphenyl)propanamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The objective of this study was to investigate the effect of the pulmonary route on the systemic absorption of FK224 in comparison with other administration routes, and to determine the bioavailability (BA) of FK224 following pulmonary administration in rats using various dosage forms."( Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta-cyclodextrin.
Ibuki, R; Kawashima, Y; Nakate, T; Ohike, A; Tokunaga, Y; Yoshida, H, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" In the presence of FK 224, SP dose-response curves and NKA dose-response curves were shifted to the right in parallel with no depression of the maximal contraction."( FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity.
Fujii, T; Kiyotoh, S; Maeda, Y; Morimoto, H; Murai, M; Nishikawa, M; Yamaoka, M, 1992
)
2.05
" Atropine (10(-6) M) and tetrodotoxin (3 x 10(-7) M) did not affect NKA-induced contractions, but inhibited SP- and NKB-induced contractions; the dose-response curves for SP and NKB were rightwardly shifted by atropine."( Tachykinin-induced contractions in the circular muscle of guinea pig ileum.
Gomi, Y; Mizuno, K; Suzuki, N, 1994
)
0.29
" FK224 (10(-6) M and 10(-5) M, respectively) significantly inhibited NKA-induced contraction and 10(-5) M FK224 shifted the dose-response curve to more than one log unit higher concentration."( Tachykinin antagonist FK224 inhibits neurokinin A-, substance P- and capsaicin-induced human bronchial contraction.
Ando, M; Fujii, K; Goto, E; Hamamoto, J; Hirata, N; Honda, I; Iwagoe, H; Kohrogi, H; Yamaguchi, T, 1997
)
0.3
" The objective of this study was to investigate the effect of the pulmonary route on the systemic absorption of FK224 in comparison with other administration routes, and to determine the bioavailability (BA) of FK224 following pulmonary administration in rats using various dosage forms."( Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta-cyclodextrin.
Ibuki, R; Kawashima, Y; Nakate, T; Ohike, A; Tokunaga, Y; Yoshida, H, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's38 (86.36)18.2507
2000's6 (13.64)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.34 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (14.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (6.82%)5.53%
Reviews2 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (88.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]